Take a look at this week's top headlines.
Women in the US are more likely to be murdered during pregnancy or soon after childbirth than to die from the country’s top 3 leading causes of maternal death—high blood pressure disorders, hemorrhage, or sepsis—according to research in The BMJ.
A study in the journal Contraception found that, within the first year of the COVID-19 pandemic in the US, abortion clinics in states with low or medium hostility to abortion were significantly more likely to embrace innovative medication abortion practices such as changing ultrasound requirements, offering telehealth or dispensing medications without a physical exam, compared to abortion clinics in states with high or extreme hostility to abortion.
The American Gastroenterological Association has released new guidance outlining the organization’s stance on evidence-based approaches to management of obesity using the latest pharmacological interventions.
Watch the latest interview in a series from members of the AUGS Publications Committee to hear from Bobby Garcia, MD, about new perspectives in cosmetic gynecology.
Federal health programs that provide services to economic and racial minorities may have a reputation for providing less empathetic or patient-centered care than private health care institutions, but a new study shows that—at least in contraceptive counseling¬—that’s not the case.
Researchers from the Feinstein Institute in Manhasset, New York, found single-cell RNA sequencing to be an effective and noninvasive way to screen for and diagnose patients with endometriosis.
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More